Pliant Therapeutics, Inc.

PLRX · United States

Share price · PLRX

$0.66-0.49 (-42.52%) 3M

close as of 2026-11-18 · 24h delayed · vol 945K (2.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PLRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Nov 2026-5.8%
  2. 15 Oct 2026+10.0%
  3. 14 Oct 2026-8.7%
  4. 25 Sep 2026-5.3%
  5. 16 Sep 2026-4.5%
  6. 20 Jul 2026-7.0%
  7. 14 Jul 2026-4.4%
  8. 16 Jun 2026+4.4%
  9. 26 Mar 2026-6.1%

    Nothing announced by PLRX that day or the session before.

  10. 12 Mar 2026+6.0%

Share of unusual movement by asset

For each asset, the share of PLRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
PLN-101095
events and moves
81%
Other company news (earnings, financing, releases naming no asset)—54%
Sessions with no dated event—46%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Integrins αvβ8 and αvβ1Small molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$18M$28M+ $115M short-term inv.$24M-$17M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$17M$26M+ $133M short-term inv.$22M-$13M operating cash flowreport ↗
2026-Q1—$14M$24M+ $149M short-term inv.$20M-$19M operating cash flowreport ↗
2025-Q3—$18M$95M+ $148M short-term inv.$26M-$21M operating cash flowreport ↗
2025-Q2—$32M$88M+ $176M short-term inv.$43M-$41M operating cash flowreport ↗
2025-Q1—$43M$93M+ $214M short-term inv.$56M-$49M operating cash flowreport ↗
2024-Q3$0$48M$81M+ $325M short-term inv.$58M-$32M operating cash flowreport ↗
2024-Q2$0$46M$82M+ $356M short-term inv.$56M-$45M operating cash flowreport ↗
2024-Q1$0$37M$116M+ $368M short-term inv.$47M-$30M operating cash flowreport ↗
2023-Q3$0$32M$58M+ $466M short-term inv.$41M-$36M operating cash flowreport ↗
2023-Q2$0.3M$33M$55M+ $500M short-term inv.$41M-$25M operating cash flowreport ↗
2023-Q1$1.3M$29M$103M+ $475M short-term inv.$38M-$30M operating cash flowreport ↗
2022-Q3$1.5M$25M$45M+ $316M short-term inv.$31M-$19M operating cash flowreport ↗
2022-Q2$5.0M$26M$25M+ $139M short-term inv.$30M-$24M operating cash flowreport ↗
2022-Q1$1.3M$21M$33M+ $146M short-term inv.$28M-$21M operating cash flowreport ↗
2021-Q3$1.6M$21M$45M+ $176M short-term inv.$27M-$23M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$109M$47M+ $146M short-term inv.$37M-$128M operating cash flowreport ↗

For fiscal year 2025, Pliant Therapeutics reported revenue of $0M (prior year: $0M), R&D spend of $109.16M, down 35.5% YoY, and cash and equivalents of $46.93M. The company reported a net loss of $149.34M and a quarterly net burn of $149.34M.

Pliant announced positive Phase 1 dose-escalation data for its lead candidate PLN-101095 in patients with immune-checkpoint-inhibitor-resistant solid tumors, including responses across the three highest dose cohorts, and plans to initiate a Phase 1b indication expansion trial in 2026. The company discontinued development of bexotegrast in IPF following a data review and is evaluating the path forward for PSC after regulatory discussions, while continuing to advance its integrin-binding molecule platform for targeted drug delivery.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$169M$73M+ $285M short-term inv.$53M-$156M operating cash flowreport ↗
2023-FY$1.6M$128M$65M+ $431M short-term inv.$40M-$116M operating cash flowreport ↗
2022-FY$9.7M$97M$34M+ $298M short-term inv.$31M-$95M operating cash flowreport ↗
2021-FY$7.6M$78M$52M+ $149M short-term inv.$24M-$75M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($164K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Raben David · Chief Medical OfficerAward / grant (derivative)575,000——Form 4
2026-07-09Borellini Flavia · directorAward / grant (derivative)60,000——Form 4
2026-07-09Iannone Robert · directorAward / grant (derivative)60,000——Form 4
2026-06-11Cline Darren S · directorAward / grant (derivative)70,000——Form 4
2026-06-11Huh Hoyoung · directorAward / grant (derivative)70,000——Form 4
2026-06-11Curnutte John T · directorAward / grant (derivative)70,000——Form 4
2026-06-11Krognes Steve E. · directorAward / grant (derivative)70,000——Form 4
2026-06-11MCCOURT Thomas A · directorAward / grant (derivative)70,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 91 reporting institutions held 49.7M shares ($58.1M, 80.1% of shares outstanding).

#InstitutionSharesValue
1TANG CAPITAL MANAGEMENT LLC6,143,132$7.7M
2CITADEL ADVISORS LLC3,226,599$4.1M
3Blue Owl Capital Holdings LP2,969,199$3.7M
4ADAR1 Capital Management, LLC2,585,126$3.3M
5VANGUARD CAPITAL MANAGEMENT LLC2,343,101$3.0M
6TWO SIGMA INVESTMENTS, LP2,253,138$2.8M
7Monaco Asset Management SAM1,938,747$2.4M
8RENAISSANCE TECHNOLOGIES LLC1,852,842$2.3M
9Prosight Management, LP1,667,600$2.1M
10Woodline Partners LP1,666,830$2.1M
11BML Capital Management, LLC1,546,137$1.9M
12Peapod Lane Capital LLC1,288,578$1.6M
13MILLENNIUM MANAGEMENT LLC1,180,518$1.5M
14BlackRock, Inc.1,096,430$1.4M
15UBS Group AG1,057,954$1.3M